Organon Reboots with Biotech
Organon's biologics R&D push relects similar moves by other mid-sized firms, and could help the company recover after a series of setbacks. But building biotech from discovery upwards will take time.
Organon's biologics R&D push relects similar moves by other mid-sized firms, and could help the company recover after a series of setbacks. But building biotech from discovery upwards will take time.